The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search instagram avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

On July 25th, the U.S. Judicial Panel on Multidistrict Litigation (JPML) will hear oral arguments regarding the consolidation of diabetic drug lawsuits involving two popular medications: Byetta & Januvia.

Byetta and Januvia, both used to treat Type 2 Diabetes have recently been associated with an increased risk of pancreatic cancer.  The diabetes and pancreatic cancer study linking Byetta and Januvia with cancer of the pancreas was published earlier this year.  However, there are already 53 pending Januvia and Byetta lawsuits brought on by plaintiffs who allege Januvia, Byetta, and other incretin mimetic diabetes medications caused them to develop Pancreatic Cancer.

The motion to centralize the diabetic drug litigation was filed in April.  If consolidated, the Multi-District Litigation (MDL) will include not only Byetta and Januvia lawsuits, but Janumet and Victoza lawsuits as well.

For additional information on diabetes, see the Diabetes-Talk Blog or “Diabetes Talk on Facebook.”

Comments for this article are closed.